Sanofi SAN.PA · PAR
74.78 € +1.64% (+1.21 €)
Summary
60 / 100 · Bulios Score
What speaks for it
- It has raised its dividend 21 years in a row.
- Out of every 100 EUR of revenue, 34 EUR is left as free cash.
- It bought back its own shares for 5.03B € in the last fiscal year, 5.9% of its market value.
- Analysts expect revenue to grow by 12% this fiscal year.
What to watch
- The share price is above the Bulios Fair Price.
- It pays out more in dividends than it earns: 125% of profit.
- Revenue grew by only 2.7% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 21.5 EUR for 1 EUR of yearly profit. Over the last five years it was 17.2 EUR on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue grew by 3.1% a year over 5 years. Over the last 3 years it grew by 2.7% a year. For the next fiscal year analysts expect revenue to grow by 12%. Earnings per share fell by 1.3% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 EUR of revenue goes
- Cost of sales 27 EUR
- Research and development 17 EUR
- Sales and administration 36 EUR
- Taxes and other 12 EUR
- Net profit 8.1 EUR
Net profit, industry median (Drug Manufacturers - General) 14 EUR
Out of every 100 EUR of revenue, 8.1 EUR is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 1.4 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
High, at risk- Yield
- 5.81%
- Paid out of profit
- 125%
- Raised in a row
- 21 years
You receive 4.12 € per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 16
- Hold 10
- Sell 4
No analyst has published a price target.
53% of the analysts recommend buying.
Analysts in detail